% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • ricardouno ricardouno Dec 10, 2012 6:33 PM Flag

    More Adcetris Data From ASH

    Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting

    - 96 Percent Complete Remission Rate in Newly Diagnosed Hodgkin Lymphoma Patients Treated with ADCETRIS in Combination with AVD Chemotherapy -

    - Safety and Response Data Support Ongoing Phase III Trial of ADCETRIS and AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin Lymphoma -

    Ricardo says: "This drug is no humbug"

    Good luck to all !

33.62-1.37(-3.92%)2:43 PMEDT